
Annual report 2025
added 04-04-2026
BioNTech SE Net Debt 2011-2026 | BNTX
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt BioNTech SE
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | -973 M | - | -357 M | -122 M | -277 M | - | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -122 M | -973 M | -432 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Celldex Therapeutics
CLDX
|
-26.5 M | $ 34.86 | 2.95 % | $ 2.32 B | ||
|
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 4.3 | 8.31 % | $ 10.3 B | ||
|
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Citius Pharmaceuticals
CTXR
|
-2.99 M | $ 0.87 | 2.3 % | $ 5.85 M | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Akari Therapeutics, Plc
AKTX
|
-5.45 M | $ 5.51 | 7.65 % | $ 371 B | ||
|
Aligos Therapeutics
ALGS
|
-132 M | $ 6.71 | -12.4 % | $ 66.3 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
-604 M | $ 306.52 | -4.25 % | $ 40.2 B | ||
|
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Forte Biosciences
FBRX
|
-58.8 M | $ 32.69 | 3.99 % | $ 423 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Galectin Therapeutics
GALT
|
-25.6 M | $ 2.43 | 7.52 % | $ 155 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
457 M | $ 22.73 | 4.22 % | $ 1.06 B | ||
|
Applied Therapeutics
APLT
|
-49.4 M | - | - | $ 8.42 M | ||
|
Galapagos NV
GLPG
|
-1.29 B | $ 29.24 | 1.3 % | $ 2.69 B | ||
|
Grifols, S.A.
GRFS
|
5.36 B | $ 8.7 | 1.16 % | $ 6.83 B | ||
|
GT Biopharma
GTBP
|
-5.5 M | $ 0.38 | -4.21 % | $ 2.1 M | ||
|
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
Hoth Therapeutics
HOTH
|
-7.01 M | $ 0.72 | -2.61 % | $ 9.94 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 3.04 | -1.17 % | $ 5 M | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
BioXcel Therapeutics
BTAI
|
56.3 M | $ 1.17 | 8.88 % | $ 14.3 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
InflaRx N.V.
IFRX
|
-32.3 M | $ 1.55 | 28.75 % | $ 152 M | ||
|
Akebia Therapeutics
AKBA
|
-133 M | $ 1.43 | 5.56 % | $ 368 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
Immutep Limited
IMMP
|
-17.4 M | $ 0.6 | 4.21 % | $ 1.08 B | ||
|
Aquestive Therapeutics
AQST
|
-75.5 M | $ 4.34 | 1.76 % | $ 464 M | ||
|
AstraZeneca PLC
AZN
|
9.86 B | - | - | $ 96.9 B | ||
|
Arcutis Biotherapeutics
ARQT
|
65.3 M | $ 24.54 | 1.45 % | $ 3.12 B | ||
|
Burford Capital Limited
BUR
|
-135 M | $ 4.91 | 5.14 % | $ 792 M | ||
|
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
533 K | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
-33.1 M | - | -4.8 % | $ 255 M | ||
|
Cabaletta Bio
CABA
|
-76.6 M | $ 3.32 | -5.68 % | $ 334 M | ||
|
Autolus Therapeutics plc
AUTL
|
-32.7 M | $ 1.65 | 2.17 % | $ 439 M |